Tag: Flibanserin
Many Patient Advocacy Organizations Are Funded By Industry
New research investigates the financial conflicts of interest (FCOI) of patient advocacy organizations (PAOs) in the United States.
“FDA Issues Guidelines for Female Libido Pills After Learning Some Hard...
From STAT: It “looks like the FDA is using this guidance to keep another company from trying to get a female sexual desire drug approved...
What Animal Research Says About Sexual Side-effects of SSRIs
A group of researchers in Denmark examines what existing animal studies can tell us about the sexual side-effects of SSRI antidepressants.
“It’s All In Her Bed (Or, Don’t Shoot the Massager)”
The drug watch blog Evidencer.org takes on Flibanserin (Addyi) the first drug claiming “to enhance women’s sexual drive…”
Article →
“Doctors on Social Media Fail to Disclose Conflicts of Interest”
“A STAT examination of hundreds of social media accounts maintained by health-care professionals finds that while they often tweet medical advice, they almost never disclose potential conflicts of...
“Study Shows Addyi is Not ‘Female Viagra’ by Any Stretch of...
Pharmaguy covers a study published in JAMA this month which found that Addyi, the new drug approved by the FDA to treat low sexual...
“Was Sexism Really Responsible for the FDA’s Hesitancy to Sign Off...
“The Food and Drug Administration’s approval of pharmaceutical treatment for low sexual desire in women has launched a heated debate over the dangers and benefits of medicalizing sex,” Maya Dusenbery writes in the Pacific Standard. Is “female Viagra” a feminist victory or a product of clever faux-feminist marketing by Big Pharma?
“Pass on the Pill or Pass Out” Campaign Warns Women About...
“The National Women’s Health Network launched the 'Pass on the Pink Pill – Or Pass Out' campaign, to warn women of the marginal benefits...
“New Pill for Boosting Female Libidos Off to a Slow Start”
Ed Silverman reports that only 80 prescriptions for Addyi, or Flibanserin, were filled in the drugs’ first two weeks on the market.
Article →
“Controversial ‘Female Viagra’ Hits the Market, New Questions Arise”
Despite concerns about the drug’s necessity, effectiveness, and side-effects, Flibanserin (Addyi) has come to market as the first drug designed to increase sexual desire in women
Members of FDA Advisory Committee Offer Perspectives on Flibanserin Approval in...
In the September issue of The Journal of the American Medical Association (JAMA) three FDA advisory committee members describe the convergence of factors that made the committee’s recommendation to approve flibanserin especially challenging and politically charged.
“Flibanserin, ‘Female Viagra,’ Distracts From Real Causes of Low Libido”
CBC News Canada voices sex therapists and psychiatrists concerns over the FDAs decision to approve Flibanserin last week. Critics contend, “it's an ineffectual pharmacological solution for a problem better treated with relationship counselling, sex therapy and behavioural changes.” Walid Gellad, the co-director of the Center for Pharmaceutical Policy and Prescribing adds, “"[I] believe that it should be used by almost no one.”
FDA Approves Controversial “Pink Viagra”
On Tuesday, the U.S. Food and Drug Administration (FDA) approved Flibanserin (Addyi) to treat low sexual desire in women despite concerns about the drug's limited efficacy and doubts over its clinical relevance. That the drug is being called the "pink Viagra" can be misleading as Viagra treats erectile dysfunction by improving blood flow while Flibanserin targets the brain, and must be taken daily.
